Research
Hormonal
Sarcopenic obesity drives cardiovascular disease and mortality through mechanisms of chronic low-grade inflammation, insulin resistance, and lipotoxicity, creating a vicious cycle with cardiovascular conditions.
Understanding that fat and muscle loss interact to cause inflammation and heart risk highlights why treating both is crucial. Managing inflammation and insulin sensitivity through lifestyle can break this cycle.
GoodSupportsHIGH confidence
Sarcopenic obesity and CVD are mutually causative and intricately interconnected... The expansion of white adipose tissue mass and the local infiltration of muscle tissue by lipid deposits leads to secretion of proinflammatory adipokines, thereby inhibiting protein synthesis and inducing protein catabolism, which exacerbate the decline in muscle mass and promotes pathological mechanisms such as insulin resistance.
Why this rating
Supported by mechanistic studies and cohort data linking the condition to CVD.
Source
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Shibo Wei et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1185221
narrative_reviewCited 243×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sarcopenic obesity, defined as the coexistence of low muscle mass/strength and high adiposity, significantly increases the risk of all-cause mortality, cardiovascular disease, and frailty compared to having either condition alone.Good
- Management of sarcopenic obesity requires a combined approach of resistance and aerobic exercise with moderate caloric restriction and high-quality protein intake, as caloric restriction alone can exacerbate muscle loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →